This is a mechanism module, not a specific disease. It is a pathological structure-formation ("Xogenesis") module. Xogenesis anchor: the terminal output is a granuloma (MPATH:847), an OGMS:0000078 pathological anatomical structure produced by an OGMS:0000081 pathological derivation (a new formation assembled from recruited and transformed cells); process genus OGMS:0000061 pathological bodily process. SNOMED "Morphologically abnormal structure" (49755003) is used only as an external census/gap guide and is not bound here. Disorder entries reference individual nodes via conforms_to (for example, "granuloma_formation#Epithelioid Transformation and Multinucleated Giant Cell Formation"). The module defines the expected pathophysiology structure; conforming nodes in disorder files should include the corresponding cell types, biological processes, and causal edges, specialized to their disease context. Key disease-specific substitutions: tuberculosis substitutes M. tuberculosis as the persistent stimulus with caseating necrosis and cavitation at the effector node; sarcoidosis substitutes an unknown antigen with non-caseating granulomas; foreign-body granulomas substitute inert particulate material and typically lack the Th1 adaptive arm. Modules bind GO and CL terms only and do not use chemical (CHEBI) or disease (MONDO) term bindings, except in the treatments block where the therapeutic agent carries an ontology identifier per the treatment schema.
Persistent Indigestible Stimulus
trigger
The proximal trigger of the granulomatous response is a persistent particulate stimulus - an infectious organism, microbial component, or inert foreign material - that resists elimination by an individual macrophage. Because the stimulus cannot be cleared by ordinary phagocytosis, it provokes a sustained, chronic macrophage response rather than resolving acute inflammation. The specific stimulus differs by disorder but the shared feature is its indigestibility and persistence.
Downstream
-
Th1 and TNF-Driven Macrophage Recruitment and Activation
Show evidence (2 references)
"These evolutionarily ancient structures form in response to persistent particulate stimuli-infectious or noninfectious-that individual macrophages cannot eradicate."
Directly identifies a persistent particulate stimulus that individual macrophages cannot eradicate as the trigger of granuloma formation. Evidence source is OTHER because this is an authoritative review (Annual Review of Immunology).
"Granulomas represent a distinct host response to chronic antigenic stimuli, such as foreign bodies, certain bacterial components, or persistent pathogens such as M. bovis."
Establishes chronic/persistent antigenic stimuli (foreign bodies, bacterial components, persistent pathogens) as the host-response trigger for granulomas. Evidence source is MODEL_ORGANISM because the study examined M. bovis-infected cattle.
Th1 and TNF-Driven Macrophage Recruitment and Activation
amplifier
Failure to clear the stimulus drives sustained recruitment of monocytes and Th1 (and Th17) lymphocytes that, through interferon-gamma and tumor necrosis factor (TNF), classically activate macrophages at the site. TNF is a non-redundant amplifier: it is required to initiate and organize the granulomatous response, which is why its pharmacological neutralization dissolves granulomas and reactivates latent tuberculosis. This activated, cytokine-rich milieu is the amplifying step that licenses the downstream macrophage transformations.
Downstream
-
Epithelioid Transformation and Multinucleated Giant Cell Formation
Show evidence (2 references)
"granulomas: a compact collection of macrophages that have differentiated into epithelioid cells and which are associated with T helper (Th)1 and Th17 cells."
Links granuloma macrophages to Th1/Th17 adaptive immunity, supporting the T-cell-driven macrophage-activation amplifier. Evidence source is OTHER because this is a review.
"TNF-alpha is critical for initiation of the granulomatous response, C5a is necessary for formation of cohesive granulomas, and IL-6 plays a key role in the granuloma maintenance response to mycobacterial TDM."
Demonstrates that TNF-alpha is critical for initiating the granulomatous response, establishing TNF as the non-redundant amplifier of this module. Evidence source is MODEL_ORGANISM because the roles were dissected in cytokine-knockout mice.
Organized Granuloma Assembly
effector
The transformed macrophages assemble into a compact, organized aggregate - an epithelioid/giant-cell core cuffed by lymphocytes and, in some diseases, surrounded by fibroblasts. In diseases such as tuberculosis the center of the granuloma undergoes caseating necrosis and can cavitate; in sarcoidosis the granuloma is characteristically non-caseating. This organized structure is the mature granuloma, the pathological anatomical entity that the module produces.
Downstream
-
Tissue Containment versus Destruction and Fibrosis
Show evidence (2 references)
"Granulomas are organized aggregates of macrophages, often with characteristic morphological changes, and other immune cells."
Defines the granuloma as an organized aggregate of macrophages with characteristic morphological changes and other immune cells, the effector structure of this module. Evidence source is OTHER because this is a review.
"The development of cavities is likely to enhance inter-host transmission and caseum could facilitate the dissemination of Mtb to other organs inducing disease progression."
Documents caseation and cavitation of the mature granuloma in tuberculosis, the disease-specific elaboration of the organized-granuloma effector. Evidence source is OTHER because this is a review.
Tissue Containment versus Destruction and Fibrosis
consequence
The clinical end state of the module is double-edged. On the protective side, the granuloma sequesters and contains the offending stimulus, limiting its spread. On the pathological side, when the stimulus persists the granuloma drives chronic host tissue destruction, necrosis, cavitation, and fibrotic scarring, which underlies the organ damage of tuberculosis, sarcoidosis, and other granulomatous diseases. Whether containment or destruction dominates is the consequence of the conserved granuloma-formation chain.
Show evidence (2 references)
"Granulomas evolved as protective responses to destroy or sequester particles but are frequently pathological in the context of foreign bodies, infections, and inflammatory diseases."
Establishes the dual protective/pathological nature of granulomas, the consequence node of this module. Evidence source is OTHER because this is a review.
"This complex granulomatous host response can be modulated by Mtb to induce pathological changes damaging host lung tissues"
Documents that the granulomatous response can produce pathological tissue-damaging changes, the destructive arm of this consequence node. Evidence source is OTHER because this is a review.
TNF Inhibitor Therapy
Platform:
Monoclonal antibody
TNF-neutralizing biologics (e.g., infliximab, adalimumab) are used to treat non-infectious granulomatous diseases such as Crohn disease and refractory sarcoidosis. Because TNF is required to initiate and maintain the granuloma, its blockade impairs granuloma integrity - therapeutic when the granulomatous inflammation is sterile, but dangerous in latent infection, where it dissolves protective granulomas and reactivates tuberculosis (a class boxed warning). Represents the granuloma-formation drug-target design pattern for conforming disorders, acting on the TNF-driven macrophage-activation node rather than on the mature structure.
Evidence: 2